Division of Cardiology, Department of Medicine, Fresno Medical Education Program, University of California San Francisco, Fresno, CA 93703, USA.
Med Clin North Am. 2012 Sep;96(5):915-31. doi: 10.1016/j.mcna.2012.07.010.
Heart failure (HF) is a major public health problem associated with increased morbidity and mortality. As the US life expectancy increases and the population ages, the overall prevalence of HF will continue to escalate. The increasing use of effective selective therapies such as neurohormonal blockade in the treatment of patients with HF has led to considerable improvement in their prognosis. During the past several decades, some studies have demonstrated the benefits of treatment; based on the evidence available from these studies, various national and international guidelines have specific recommendations for the evidence-based therapy with these drugs in patients with HF.
心力衰竭（HF）是一个与发病率和死亡率增加相关的主要公共卫生问题。随着美国预期寿命的延长和人口老龄化，HF 的总体患病率将继续上升。在 HF 患者的治疗中越来越多地使用有效的选择性治疗方法，如神经激素阻断，已导致其预后有了相当大的改善。在过去几十年中，一些研究已经证明了治疗的益处；基于这些研究中可用的证据，各种国家和国际指南都对 HF 患者使用这些药物的循证治疗有具体建议。
